Compositions and methods of use for modified release minoxidil
The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.
1. A method of treating hair loss, comprising orally administering to a subject in need thereof a modified release pharmaceutical formulation comprising from about 3.5 mg to about 20 mg of minoxidil or a pharmaceutically acceptable salt thereof; wherein wherein the modified release pharmaceutical formulation provides:
a blood level of the minoxidil or a pharmaceutically acceptable salt thereof of about 1 ng/ml to about 20 ng/ml;
a Cmax of about 0.25 ng/ml to about 20 ng/ml; and
a Tmax of about 30 to about 360 minutes.
2. The method of claim 1 , wherein the modified release pharmaceutical formulation further comprises a release modifier, a filler, a glidant, a lubricant, and combinations thereof.
3. The method of claim 1 , wherein the subject in need thereof is diagnosed with hair loss.
4. The method of claim 3 , wherein the hair loss is selected from male pattern hair loss, female pattern hair loss, hereditary hair loss, telogen effluvium, alopecia areata, central centrifugal cicatricial alopecia, lichen planopilaris, or traction alopecia.
5. The method of claim 1 , wherein administering results in hair regrowth.
6. The method of claim 1 , wherein the modified release pharmaceutical formulation comprises an enteric coating.
7. The method of claim 1 , wherein the modified release pharmaceutical formulation is administered at least once daily.
8. The method of claim 1 , wherein the oral administration of the modified release pharmaceutical formulation results in substantially no cardiac effects.
9. The method of claim 8 , wherein the cardiac effects are selected from tachycardia, hypotension, premature ventricular contractions, and other tachyarrhythmias.
10. The method of claim 1 , wherein the modified release pharmaceutical formulation provides a blood level of minoxidil or a pharmaceutically acceptable salt thereof that is maintained for at least about 12 hours.
11. The method of claim 1 , wherein about 4.5 mg, about 8.5 mg, about 9 mg, about 17 mg, or about 20 mg of the minoxidil is administered per day.
12. The method of claim 2 , wherein the release modifier is present in an amount of about 50% to about 80% (w/w) of the total formulation.
13. The method of claim 1 , wherein the oral administration of the modified release pharmaceutical formulation provides an AUC of minoxidil that is less than an AUC of minoxidil provided by an immediate release formulation containing an equivalent dose of minoxidil.
14. A method of treating hair loss, comprising orally administering to a subject in need thereof a modified release pharmaceutical formulation comprising about 4.5 mg of minoxidil or a pharmaceutically acceptable salt thereof; wherein the modified release pharmaceutical formulation provides:
a blood level of the minoxidil or a pharmaceutically acceptable salt thereof of about 1 ng/ml to about 20 ng/ml;
a Cmax of about 0.25 ng/ml to about 20 ng/ml; and
a Tmax of about 30 to about 360 minutes.
15. The method of claim 14 , wherein the modified release pharmaceutical formulation further comprises a release modifier, a filler, a glidant, a lubricant, and combinations thereof.
16. The method of claim 15 , wherein the release modifier is present in an amount of about 50% to about 80% (w/w) of the total formulation.
17. The method of claim 14 , wherein the oral administration provides an AUC of minoxidil that is less than an AUC of minoxidil that is provided by an immediate release formulation containing an equivalent dose of minoxidil.
18. A method of treating hair loss, comprising orally administering to a subject in need thereof a modified release pharmaceutical formulation comprising about 9 mg of minoxidil or a pharmaceutically acceptable salt thereof; wherein the modified release pharmaceutical formulation provides:
a blood level of the minoxidil or a pharmaceutically acceptable salt thereof of about 1 ng/ml to about 20 ng/ml;
a Cmax of about 0.25 ng/ml to about 20 ng/ml; and
a Tmax of about 30 to about 360 minutes.
19. The method of claim 18 , wherein the modified release pharmaceutical formulation provides a blood level of the daily dose of minoxidil or a pharmaceutically acceptable salt thereof is maintained for at least about 12 hours.
20. The method of claim 18 , wherein the modified release pharmaceutical formulation further comprises a release modifier, a filler, a glidant, a lubricant, and combinations thereof.
21. The method of claim 20 , wherein the release modifier is present in an amount of about 50% to about 80% (w/w) of the total formulation.
22. The method of claim 18 , wherein the modified release formulation provides an AUC of minoxidil that is less than an AUC of minoxidil provided by an immediate release formulation containing an equivalent dose of minoxidil.
23. The method of claim 18 , wherein the modified release pharmaceutical formulation is administered once per day, two times per day, or four times per day.
24. A method of treating hair loss, comprising orally administering to a subject in need thereof a daily dose of minoxidil or a pharmaceutically acceptable salt thereof; wherein the daily dose is from about 3.5 mg to about 20 mg; and the oral administration provides:
a blood level of the minoxidil or a pharmaceutically acceptable salt thereof of about 1 ng/ml to about 20 ng/ml, and
a Cmax of about 0.25 ng/ml to about 20 ng/ml; and
a Tmax of about 30 to about 360 minutes.
25. The method of claim 24 , wherein the oral administration provides a blood level of the daily dose of minoxidil or a pharmaceutically acceptable salt thereof that is maintained for at least about 12 hours.
26. The method of claim 24 , wherein the oral administration provides an AUC of minoxidil that is less than an AUC of minoxidil provided by an immediate release formulation containing an equivalent dose of minoxidil.
27. The method of claim 24 , wherein minoxidil is administered in a modified release pharmaceutical formulation comprising a release modifier, a filler, a glidant, a lubricant, and combinations thereof.
28. The method of claim 27 , wherein the release modifier is present in an amount of about 50% to about 80% (w/w) of the total formulation.
29. The method of claim 27 , wherein the modified release pharmaceutical formulation is administered one time per day, two times per day, or four times a day.